JP7199146B2 - ブリモニジン及びチモロールの固定用量合剤 - Google Patents

ブリモニジン及びチモロールの固定用量合剤 Download PDF

Info

Publication number
JP7199146B2
JP7199146B2 JP2017548997A JP2017548997A JP7199146B2 JP 7199146 B2 JP7199146 B2 JP 7199146B2 JP 2017548997 A JP2017548997 A JP 2017548997A JP 2017548997 A JP2017548997 A JP 2017548997A JP 7199146 B2 JP7199146 B2 JP 7199146B2
Authority
JP
Japan
Prior art keywords
composition
timolol
brimonidine
brimonidine tartrate
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017548997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508545A (ja
Inventor
ジム ジャオ
チン－ミン チャン
アヌラダ ヴイ ゴア
リチャード エス グラハム
アール スコット ジョーダン
セシャ ニアヴァナン
チェタン ピー プジャラ
ジエ シェン
ケヴィン エス ワーナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2018508545A publication Critical patent/JP2018508545A/ja
Priority to JP2021040110A priority Critical patent/JP2021102626A/ja
Application granted granted Critical
Publication of JP7199146B2 publication Critical patent/JP7199146B2/ja
Priority to JP2023062494A priority patent/JP2023086773A/ja
Priority to JP2025049992A priority patent/JP2025100564A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2017548997A 2015-03-19 2016-03-17 ブリモニジン及びチモロールの固定用量合剤 Active JP7199146B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021040110A JP2021102626A (ja) 2015-03-19 2021-03-12 ブリモニジン及びチモロールの固定用量合剤
JP2023062494A JP2023086773A (ja) 2015-03-19 2023-04-07 ブリモニジン及びチモロールの固定用量合剤
JP2025049992A JP2025100564A (ja) 2015-03-19 2025-03-25 ブリモニジン及びチモロールの固定用量合剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135320P 2015-03-19 2015-03-19
US62/135,320 2015-03-19
PCT/US2016/022874 WO2016149498A1 (en) 2015-03-19 2016-03-17 Fixed dose combination of bromonidine and timolol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021040110A Division JP2021102626A (ja) 2015-03-19 2021-03-12 ブリモニジン及びチモロールの固定用量合剤

Publications (2)

Publication Number Publication Date
JP2018508545A JP2018508545A (ja) 2018-03-29
JP7199146B2 true JP7199146B2 (ja) 2023-01-05

Family

ID=55640942

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017548997A Active JP7199146B2 (ja) 2015-03-19 2016-03-17 ブリモニジン及びチモロールの固定用量合剤
JP2021040110A Pending JP2021102626A (ja) 2015-03-19 2021-03-12 ブリモニジン及びチモロールの固定用量合剤
JP2023062494A Pending JP2023086773A (ja) 2015-03-19 2023-04-07 ブリモニジン及びチモロールの固定用量合剤
JP2025049992A Pending JP2025100564A (ja) 2015-03-19 2025-03-25 ブリモニジン及びチモロールの固定用量合剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021040110A Pending JP2021102626A (ja) 2015-03-19 2021-03-12 ブリモニジン及びチモロールの固定用量合剤
JP2023062494A Pending JP2023086773A (ja) 2015-03-19 2023-04-07 ブリモニジン及びチモロールの固定用量合剤
JP2025049992A Pending JP2025100564A (ja) 2015-03-19 2025-03-25 ブリモニジン及びチモロールの固定用量合剤

Country Status (9)

Country Link
US (3) US20180078500A1 (https=)
EP (2) EP3270892B1 (https=)
JP (4) JP7199146B2 (https=)
KR (1) KR20170129823A (https=)
CN (1) CN107427460A (https=)
AU (3) AU2016233125A1 (https=)
CA (1) CA2977825A1 (https=)
HK (1) HK1246689A1 (https=)
WO (1) WO2016149498A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
WO2019112030A1 (ja) * 2017-12-08 2019-06-13 千寿製薬株式会社 水溶性高分子を含む水性液剤
WO2019216395A1 (ja) * 2018-05-11 2019-11-14 千寿製薬株式会社 眼科用組成物
WO2019223748A1 (zh) * 2018-05-25 2019-11-28 爱博诺德(北京)医疗科技股份有限公司 粘弹剂材料
JP7630944B2 (ja) * 2019-09-12 2025-02-18 千寿製薬株式会社 ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物
GR1010024B (el) * 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
WO2023086878A1 (en) 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects
CN115671037A (zh) * 2022-11-21 2023-02-03 山东诺明康药物研究院有限公司 一种溴莫尼定噻吗洛尔pH敏感型原位凝胶及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523316A (ja) 2002-04-19 2005-08-04 アラーガン、インコーポレイテッド 眼科局所用のブリモニジンとチモロールとの組み合わせ
JP2008521812A (ja) 2004-11-24 2008-06-26 メドポイント ヘルスケア インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
JP2009533462A (ja) 2006-04-10 2009-09-17 アラーガン、インコーポレイテッド ブリモニジンおよびチモロールの組成物
WO2011087790A1 (en) 2009-12-22 2011-07-21 Allergan, Inc. Triple combination for lowering intraocular pres sure
JP2014501748A (ja) 2010-12-21 2014-01-23 リコファーマ アーベー 涙代用物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
CA2416169C (en) * 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
PL360707A1 (en) * 2000-07-14 2004-09-20 Allergan Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
HUE040283T2 (hu) * 2010-07-29 2019-02-28 Allergan Inc Brimonidin és timolol tartalmú, tartósítószer-mentes oldatok
ES2818073T3 (es) * 2013-12-24 2021-04-09 Sentiss Pharma Private Ltd Solución oftálmica de tartrato de brimonidina tópica
US20160331746A1 (en) * 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523316A (ja) 2002-04-19 2005-08-04 アラーガン、インコーポレイテッド 眼科局所用のブリモニジンとチモロールとの組み合わせ
JP2008521812A (ja) 2004-11-24 2008-06-26 メドポイント ヘルスケア インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
JP2009533462A (ja) 2006-04-10 2009-09-17 アラーガン、インコーポレイテッド ブリモニジンおよびチモロールの組成物
WO2011087790A1 (en) 2009-12-22 2011-07-21 Allergan, Inc. Triple combination for lowering intraocular pres sure
JP2014501748A (ja) 2010-12-21 2014-01-23 リコファーマ アーベー 涙代用物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｃｕｒｒ．Ｍｅｄ．Ｒｅｓ．Ｏｐｉｎ．，２００８年，Ｖｏｌ．２４，ｐｐ．２０３５－２０４３

Also Published As

Publication number Publication date
EP4420726A2 (en) 2024-08-28
US20250387325A1 (en) 2025-12-25
CA2977825A1 (en) 2016-09-22
EP4420726A3 (en) 2024-11-13
JP2021102626A (ja) 2021-07-15
US20180078500A1 (en) 2018-03-22
JP2018508545A (ja) 2018-03-29
EP3270892B1 (en) 2024-04-10
AU2023208076A1 (en) 2023-08-10
WO2016149498A1 (en) 2016-09-22
US20220370346A1 (en) 2022-11-24
KR20170129823A (ko) 2017-11-27
CN107427460A (zh) 2017-12-01
AU2021203665A1 (en) 2021-09-02
JP2025100564A (ja) 2025-07-03
AU2016233125A1 (en) 2017-09-14
EP3270892A1 (en) 2018-01-24
HK1246689A1 (zh) 2018-09-14
JP2023086773A (ja) 2023-06-22

Similar Documents

Publication Publication Date Title
JP7199146B2 (ja) ブリモニジン及びチモロールの固定用量合剤
AU2023282222B2 (en) Low-dose brimonidine combinations and uses thereof
US10792288B2 (en) Preservative free brimonidine and timolol solutions
JP2004107335A (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
WO2012106537A1 (en) Compositions and methods for treatment of glaucoma
KR102901189B1 (ko) 피리딜아미노아세트산 화합물을 함유하는 의약 제제
JP7247278B2 (ja) 水性医薬組成物
JP2011011984A (ja) 仮性近視治療薬
US20210369706A1 (en) Low-dose brimonidine combinations and uses thereof
HK40020724A (en) Low-dose brimonidine combinations and uses thereof
US20140275200A1 (en) Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210312

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210325

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210423

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210426

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210528

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210603

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220406

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221013

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20221031

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20221128

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221220

R150 Certificate of patent or registration of utility model

Ref document number: 7199146

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250